ASTERDM share price target 2026

BazaarBaazi does not publish a SEBI-registered price target on ASTERDM. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.

The BazaarBaazi Crack Score for ASTERDM is 89 out of 100 as of 25 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.

Strike-level option inventory for ASTERDM is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.

ASTERDM sits in Healthcare (mid cap), indicative market cap ~45,930 cr (indicative), ISIN INE914M01019. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on Aster DM Healthcare Limited: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.

This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on ASTERDM is bullish, published in Systematic Read on 21 Jul 2026.

On the 2026-07-24 run of the 500-name BazaarBaazi setup scanner, Aster DM Healthcare Limited sits in the Watchlist tier with a setup score of 92/100 (technical 100, fundamental 100). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.

BazaarBaazi indexes 19 ASTERDM earnings calls going back to 2022-05-31, latest 2026-06-30. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.

Aster DM Healthcare Limited reported a net profit of Rs 154 cr for Q4 FY26 (the quarter ended 31 March 2026). That is +79.5% year on year. The figure is from the company's official NSE filing.

Aster DM Healthcare Limited reported revenue of Rs 1,182 cr for Q4 FY26. That is +18.2% year on year. The figure is from the company's official NSE filing.

BazaarBaazi gives Aster DM Healthcare Limited's Q4 FY26 result a Result Pulse of 97 out of 100, with a verdict of Profit acceleration. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.

Aster DM Healthcare Ltd's two most material recent disclosures are a disclosure dated 23 Jul 2026, "ASTERDM: Members of the Exchange are hereby informed that…", and a m&a dated 13 Jul 2026, "allotment of equity shares to the shareholders of…". Both link to the company's own official filing on the BazaarBaazi stock page.

Yes. Aster DM Healthcare Ltd filed a dividend disclosure on 02 Apr 2026, filed as "Interim Dividend - Rs 3 Per Share". Any amount shown is the exchange's own record, linked from the BazaarBaazi stock page. A dividend is a declared payout, not a forecast of future returns.

Aster DM Healthcare Ltd's most recent board-meeting disclosure on record dated 02 Jul 2026 reads "updated outcome of the Board Meeting held on Wednesday, 1 July 2026…". That is the agenda as filed with the exchange, linked from the BazaarBaazi stock page, and BazaarBaazi adds no claim of its own to it.

Aster DM Healthcare Ltd filed a credit-rating disclosure on 10 Jul 2026, recorded with the exchange as "Credit Rating- Revision". The detail sits in the linked filing on the BazaarBaazi stock page. A rating action is an agency view on debt, separate from the share price.